Medtronic Inc. (NYSE:MDT) said two-year results from a clinical study demonstrate the durability and efficacy of its CoreValve cather-based heart valve replacement system.
Cardiac Implants
NMT Medical adds cardiologist to board
NMT Medical Inc. (NSDQ:NMTI) tapped cardiologist Paul Kramer, MD, for its board of directors.
The 59-year-old Kramer is the eighth member of the board; nine-year director Cheryl Clarkson will not stand for re-election at the company’s July shareholder meeting.
In a prepared statement, chairman James Mahoney Jr. said Kramer has an intimate familiarity with NMT Medical’s minimally invasive, catheter-based implant technology for percutaneous cardiovascular interventions.
NMT’s Q1 losses double on warrants write-down
First-quarter net losses for NMT Medical Inc. (NSDQ:NMTI) more than doubled on a write-down of warrants the company issued in February as part of a $5.8 million private placement.
The Boston-based cardiac implant maker posted net losses of $7.9 million, or 54 cents per share, during the three months ended March 31, compared with net losses of $3.8 million, or 29 cents per share, during the same period last year.
NMT Medical registers for another $30 million offering
NMT Medical Inc. (NSDQ:NMTI) isn’t letting a little snow get in its way. Having salvaged an offering of stock, debt and warrants delayed by a February blizzard with a $6 million private placement, the company filed another registration for a similar, $30 million public offering with the Securities and Exchange Commission.
Medtronic wins a round in valve patent fight against Edwards
Medtronic Inc. (NYSE:MDT) won a round in its patent fight against Edwards Lifesciences Inc. (NYSE:EW), as the medical device giants prepare for a showdown in the U.S. District Court for Delaware in late March over a patent involving an aortic valve replacement.
The Appellate Court of Düsseldorf, Germany, upheld a German lower court’s ruling that Medtronic’s CoreValve transcatheter aortic valve does not infringe on Edwards Lifesciences’s German patent.
The CoreValve system is designed to enable the replacement of a diseased aortic valve without open heart surgery. Edwards claimed the technology infringed on a patent it held in Germany and has filed similar suits in the U.K. and the U.S.
NMT Medical pushes up StarFlex trial
NMT Medical Inc. plans to begin analyzing the data from a clinical trial of its StarFlex cardiac implant ahead of schedule.
The Boston-based device maker said it will begin analyzing data from the CLOSURE I clinical trial of its StarFlex implant in April of next year, ahead of its fall 2010 target date.
MedTech Monday: Are IV bags the next fashion statement?
Turn your post-op recovery into a fashion statement: With designer Olivier Trillon’s concepts, you can choose between an Yves Saint Laurent or Chanel IV bag for your post-op morphine drip.
NMT Medical’s StarFlex implant cleared for ventricular repair
NMT Medical Inc.’s StarFlex ventricular septum repair implant landed pre-market approval from the federal Food & Drug Administration.
The Boston-based company’s device is designed to be inserted into the hearts of patients with defects in the wall between the ventricular chambers.
The StarFlex implant closes the defect, preventing already-oxygenated blood from returning to the lungs before being pumped back into the body.
NMT Medical pushes back StarFlex trial release
NMT Medical Inc. said it will release data from the clinical trial of its StarFlex implant.
Analysis of data from the study, which aims to determine whether the device can help prevent stroke or ischemia from patent formane ovale, is due to be released during the fourth quarter of 2010. PFO is a defect in the septum separating the heart’s atrial chambers.
The StarFlex implant closes the defect, preventing venous blood from returning to the body without being oxygenated by the lungs.